Table 2. – Use of medication by patients with Acute Coronary Syndrome at the admission stage.
| Medication | Unstable Angina | AMI without ST elevation | AMI with ST elevation | Total | p |
|---|---|---|---|---|---|
| ASA | 1399/1449 (96.5%) | 1580/1615 (97.8%) | 1688/1713 (98.5%) | 4667/4777 (97.7%) | 0.001 |
| Betablocker | 1144/1449 (79%) | 1323/1615 (81.9%) | 1352/1713 (78.9%) | 3819/4777 (79.9%) | 0.052 |
| P2Y12 inhibitor | 1239/1449 (85.5%) | 1483/1615 (91.8%) | 1671/1713 (97.5%) | 4393/4777 (92%) | <0.001 |
| Clopidogrel | 1213/1449 (83.7%) | 1401/1615 (86.7%) | 1531/1713 (89.4%) | 4145/4777 (86.8%) | <0.001 |
| Prasugrel | 11/1449 (0.8%) | 17/1615 (1.1%) | 15/1713 (0.9%) | 43/4777 (0.9%) | 0.685 |
| Ticagrelor | 23/1449 (1.6%) | 80/1615 (5%) | 149/1713 (8.7%) | 252/4777 (5.3%) | <0.001 |
| Parenteral Anticoagulant | 1151/1449 (79.4%) | 1468/1615 (90.9%) | 1500/1713 (87.6%) | 4119/4777 (86.2%) | <0.001 |
| Enoxaparina | 837/1449 (57.8%) | 1039/1615 (64.3%) | 1086/1713 (63.4%) | 2962/4777 (62%) | <0.001 |
| Fondaparinux | 113/1449 (7.8%) | 206/1615 (12.8%) | 174/1713 (10.2%) | 493/4777 (10.3%) | <0.001 |
| Unfractionated heparin | 214/1449 (14.8%) | 240/1615 (14.9%) | 282/1713 (16.5%) | 736/4777 (15.4%) | 0.319 |
| GP IIb/IIIa Inhibitors | 23/1449 (1.6%) | 91/1615 (5.6%) | 292/1713 (17%) | 406/4777 (8.5%) | <0.001 |
| Abciximab | 3/1449 (0.2%) | 10/1615 (0.6%) | 119/1713 (6.9%) | 132/4777 (2.8%) | <0.001 |
| Tirofiban | 20/1449 (1.4%) | 82/1615 (5.1%) | 173/1713 (10.1%) | 275/4777 (5.8%) | <0.001 |
| ACE inhibitor | 890/1449 (61.4%) | 1059/1615 (65.6%) | 1263/1713 (73.7%) | 3212/4777 (67.2%) | <0.001 |
| Statin | 1302/1449 (89.9%) | 1467/1615 (90.8%) | 1576/1713 (92%) | 4345/4777 (91%) | 0.108 |
| Lovastatin | 0/1293 (0%) | 0/1461 (0%) | 1/1568 (0.1%) | 1/4322 (0%) | |
| Pravastatin | 40/1293 (3.1%) | 44/1461 (3%) | 56/1568 (3.6%) | 140/4322 (3.2%) | |
| Sinvastatin | 581/1293 (44.9%) | 619/1461 (42.4%) | 914/1568 (58.3%) | 2114/4322 (48.9%) | |
| Rosuvastatin | 102/1293 (7.9%) | 103/1461 (7%) | 60/1568 (3.8%) | 265/4322 (6.1%) | |
| Atorvastatin | 570/1293 (44.1%) | 695/1461 (47.6%) | 537/1568 (34.2%) | 1802/4322 (41.7%) | |
| Dual antiplatelet therapy | 1211/1449 (83.6%) | 1463/1615 (90.6%) | 1649/1713 (96.3%) | 4323/4777 (90.5%) | <0.001 |
| Complete therapy | 787/1449 (54.3%) | 1062/1615 (65.8%) | 1116/1713 (65.1%) | 2965/4777 (62.1%) | <0.001 |
P-value: Chi-square test. Dual antiplatelet therapy: Aspirin and P2Y12 inhibitor. Complete therapy: Dual antiplatelet therapy, Parenteral Anticoagulant, Statin and Betablocker.